A representative flow cytometry (FACS)-based gating strategy is displayed in Fig. 1a, whereby AML-blasts were defined as CD117+ and/or CD34+ cells during initial AML diagnosis. The gene discussed is CD34; the disease is acute myeloid leukemia.